Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepcortespenlisimut-l
- Development stage
- Phase 3
- Lead developer
- Immunitor
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Hepcortespenlisimut-L (V5) is an orally administered therapeutic vaccine developed by Immunitor for the treatment of chronic hepatitis B (HBV) and hepatitis C (HCV) infections. The product consists of heat-inactivated, pooled blood-derived antigens obtained from HBV and HCV-positive donors, which are formulated into a tablet. Its mechanism of action is centered on immune modulation, potentially through the induction of oral tolerance or the stimulation of mucosal immunity, aimed at suppressing viral replication and reducing hepatic inflammation. Unlike traditional antiviral therapies, Hepcortespenlisimut-L is designed to be a low-cost, side-effect-free immunotherapy suitable for use in resource-limited settings. Clinical development has progressed through Phase 2 and Phase 3 trials, particularly in regions like Thailand, Vietnam, and Mongolia, where it has demonstrated efficacy in reducing viral load and improving liver function markers.
- Brand names
- Hepatovir
- Other names
- Hepcortespenlisimut-LOral Hepatitis C vaccineHBV/HCV therapeutic vaccine
Beyond the preview
Go deeper on hepcortespenlisimut-l.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepcortespenlisimut-l.